Public Health, Department of Social Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
EBioMedicine. 2016 Oct;12:68-71. doi: 10.1016/j.ebiom.2016.09.001. Epub 2016 Sep 2.
Transforming growth factor-β1 (TGF-β1) reportedly acts as a tumor suppressor in tumorigenesis. However, little is known as to how TGF-β1 concentrations change prior to the development of hepatocellular carcinoma (HCC) in humans. We examined the association between the serum TGF-β1 concentrations and death from HCC to determine whether the serum TGF-β1 can be a predictor of incident HCC.
We conducted a nested case-controlled study of participants in the Japan Collaborative Cohort Study for Evaluation of Cancer Risk. We used a conditional logistic regression analysis to estimate the adjusted relative risks (aRRs) of death from HCC according to the serum TGF-β1 concentrations among 1940 participants including 83 patients with HCC and 1857 controls matched for age, sex, and hepatitis C virus (HCV)-antibody seropositivity.
When serum TGF-β1 was modelled as a continuous variable, the aRR of death from HCC associated with a decrement of 7.9ng/mL (one standard deviation) in the serum TGF-β1 concentrations was 2.3 (95% CI 1.7-3.0, P<0.001) for all the subjects. The area under the receiver operating characteristic curve for the serum TGF-β1 concentrations was 0.78 (P<0.05).
Our finding suggests that TGF-β1 serves as a predictor for HCC.
转化生长因子-β1（TGF-β1）据报道在肿瘤发生中起肿瘤抑制作用。然而，人们知之甚少的是，在人类肝癌（HCC）发展之前，TGF-β1 浓度如何变化。我们检查了血清 TGF-β1 浓度与 HCC 死亡之间的关联，以确定血清 TGF-β1 是否可以作为 HCC 事件的预测因子。
我们对日本癌症风险评估合作队列研究的参与者进行了嵌套病例对照研究。我们使用条件逻辑回归分析，根据包括 83 例 HCC 患者和 1857 名年龄、性别和丙型肝炎病毒（HCV）抗体阳性相匹配的对照者在内的 1940 名参与者的血清 TGF-β1 浓度，估计 HCC 死亡的校正相对风险（aRR）。
当将血清 TGF-β1 建模为连续变量时，血清 TGF-β1 浓度降低 7.9ng/mL（一个标准差）与所有受试者 HCC 死亡的 aRR 相关，为 2.3（95%CI 1.7-3.0，P<0.001）。血清 TGF-β1 浓度的受试者工作特征曲线下面积为 0.78（P<0.05）。
我们的发现表明 TGF-β1 可作为 HCC 的预测因子。
